Blackstone, a global private equity heavyweight, signed on to buy BioMed Realty for $8 billion, picking up one of the life sciences industry's largest leasers of lab and office space.
Roche is investing in an early-stage project that takes a novel approach to treating autoimmune diseases, agreeing to pay up to $580 million for California's Adheron Therapeutics.
Boston Scientific announced that it has obtained an exclusive $200 million option to acquire Israel's MValve Technologies, maker of a transcatheter mitral valve replacement system for mitral regurgitation. Boston Scientific also said it is providing additional financing to the company in anticipation of a first in-human clinical trial.
Some analysts have never been all that keen on Mylan's hostile quest for Perrigo. But some forthcoming obstacles for Perrigo's businesses now have at least one questioning the deal's logic even further.
The venture capital market remains weak, but M&A activity is still strong and R&D spending is on an upward trend, conclude two state-of-the-industry reports released by EY (formerly Ernst & Young) and EvaluateMedTech and at the annual AdvaMed industry conference.
HeartWare was up about 5% in early trading on the news that activist investor Engaged Capital is opposing its acquisition of mitral valve player Valtech Cardio--and is seeking a renewed focus on LVAD with a possible sale of the company. If the deal is not terminated, Engaged Capital said it will continue to oppose it and seek board representation.
AtriCure said it will buy startup nContact as well as narrow its 2015 revenue guidance to the high end of a previously disclosed range. The public cardiac player, which is focused on atrial fibrillation and left atrial appendage management, will purchase the cardiac ablation company for $8 million in upfront cash, 3.7 million in AtriCure shares and up to $50 million in additional regulatory milestones.
Veeva Systems bought its nearest competitor in life science content management systems, Zinc Ahead, in a $130 million purchase that will combine the top two companies in the specialized field.
Getting patients to stick to their meds is a big problem in treating pulmonary diseases. So to boost adherence for its respiratory portfolio, Teva Pharmaceuticals is turning to technology.
Last month, names like Sanofi, Pfizer, Abbott and Takeda were flying around as potential suitors for Mexico-based Representaciones e Investigaciones Medicas, aka Rimsa. But it's Teva that's emerged victorious in the field.